Cited 17 times in
Adjuvant rituximab treatment for pemphigus: A retrospective study of 45 patients at a single center with long-term follow up
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김수찬 | - |
dc.contributor.author | 이상은 | - |
dc.contributor.author | 최유리 | - |
dc.contributor.author | 임정민 | - |
dc.date.accessioned | 2018-07-20T07:52:25Z | - |
dc.date.available | 2018-07-20T07:52:25Z | - |
dc.date.issued | 2017 | - |
dc.identifier.issn | 0385-2407 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/160616 | - |
dc.description.abstract | To evaluate the long-term outcomes of rituximab in the treatment of pemphigus and the influence of disease duration and different dose of rituximab on the clinical response, 45 patients with refractory pemphigus treated with at least one cycle of two infusions of rituximab (375 mg/m2 per infusion weekly) were retrospectively studied. All patients were followed up for more than 2 years. All patients achieved complete or partial remission within 8 months of the first cycle. Thirty-four (76%) patients relapsed at a median of 17 months. All patients who received additional cycles after relapse achieved new remissions. Early use of rituximab within 1 year of disease duration and high-dose therapy induced better outcomes, although the results in early use were not statistically significant. Acute respiratory distress syndrome occurred in one patient. Rituximab is effective in treating pemphigus, but relapses are frequent during long-term follow up, and additional cycles are beneficial in relapsed cases. Early and high-dose rituximab therapy may be more effective. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Wiley-Blackwell | - |
dc.relation.isPartOf | JOURNAL OF DERMATOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aged, 80 and over | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Immunologic Factors/administration & dosage* | - |
dc.subject.MESH | Immunologic Factors/adverse effects | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Pemphigus/drug therapy* | - |
dc.subject.MESH | Recurrence | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Rituximab/administration & dosage* | - |
dc.subject.MESH | Rituximab/adverse effects | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Adjuvant rituximab treatment for pemphigus: A retrospective study of 45 patients at a single center with long-term follow up | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Dermatology | - |
dc.contributor.googleauthor | Tae Hyung Kim | - |
dc.contributor.googleauthor | Yuri Choi | - |
dc.contributor.googleauthor | Sang Eun Lee | - |
dc.contributor.googleauthor | Jung Min Lim | - |
dc.contributor.googleauthor | Soo‐Chan Kim | - |
dc.identifier.doi | 10.1111/1346-8138.13757 | - |
dc.contributor.localId | A00637 | - |
dc.contributor.localId | A02826 | - |
dc.contributor.localId | A04132 | - |
dc.relation.journalcode | J01372 | - |
dc.identifier.eissn | 1346-8138 | - |
dc.identifier.pmid | 28186358 | - |
dc.identifier.url | https://onlinelibrary.wiley.com/doi/abs/10.1111/1346-8138.13757 | - |
dc.subject.keyword | early use | - |
dc.subject.keyword | pemphigus | - |
dc.subject.keyword | relapse | - |
dc.subject.keyword | retreatment | - |
dc.subject.keyword | rituximab | - |
dc.contributor.alternativeName | Kim, Soo Chan | - |
dc.contributor.alternativeName | Lee, Sang Eun | - |
dc.contributor.alternativeName | Choi, Yu Ri | - |
dc.contributor.affiliatedAuthor | Kim, Soo Chan | - |
dc.contributor.affiliatedAuthor | Lee, Sang Eun | - |
dc.contributor.affiliatedAuthor | Choi, Yu Ri | - |
dc.citation.volume | 44 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 615 | - |
dc.citation.endPage | 620 | - |
dc.identifier.bibliographicCitation | JOURNAL OF DERMATOLOGY, Vol.44(6) : 615-620, 2017 | - |
dc.identifier.rimsid | 40026 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.